Skip to content

Press Release · Press Releases · Asia-Pacific

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Issued by PR Newswire

Image: PR Newswire

- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia and New Zealand - - Audax will fund and continue DAX-044 development into Phase 1 - - Total potential...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

/C O R R E C T I O N - U.S. Gold Corp./

In the news release, U.S. Gold Corp. to Participate in the Emerging Growth Conference October 29, 2026, issued 27-Oct-2026 by U.S. Gold Corp. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at...

PR Newswire ·